Did you find this information helpful?
Deninta 60mg Injection
Salt Composition : Denosumab
Manufacturer : INTAS PHARMACEUTICALS LTD
Origin of Medicine : India
1 Prefilled Syringe(s) Of 1ml
Introduction to Deninta 60mg Injection
Deninta 60mg Injection consists of the active ingredient Denosumab. It is a medication used to treat osteoporosis, characterized by weakened bones. It is also prescribed to prevent bone complications in patients with certain types of cancer, such as multiple myeloma and bone metastases. Deninta 60mg Injection works by inhibiting a protein called RANK ligand, which plays a role in the breakdown of bone tissue. Studies proved it can significantly increase bone density, reducing fracture risk in postmenopausal women with osteoporosis and patients with cancer-related bone loss. Close monitoring of renal function may be necessary for patients with moderate renal impairment.
Deninta 60mg Injection should not be used in individuals with known hypersensitivity or allergic reactions to its components. Adequate calcium and vitamin D supplementation is required to ensure during the treatment. It is not approved for use in children and adolescents. Its safety and effectiveness in pediatric populations have not been established, so its use is contraindicated in individuals under 18. This medication should be used cautiously in individuals with pre-existing hypoparathyroidism, characterized by low parathyroid hormone levels.
Uses of Deninta 60mg Injection
Deninta 60mg Injection is used in the treatment of the following condition:
- Bone loss due to hormonal therapy in breast or prostate cancer
- Multiple myeloma (cancer affects plasma cells in the bone marrow)
- Bone metastases (cancer that spreads to bone)
Therapeutic Effects of Deninta 60mg Injection
Deninta 60mg Injection has therapeutic effects that include reducing fracture risk, increasing bone mineral density, and improving overall bone health. By inhibiting bone resorption through its action on RANK ligands, this medication helps to strengthen bones and decrease the likelihood of fractures in individuals with osteoporosis or those at high risk. It also increases bone mineral density, an important marker of bone strength. These therapeutic effects contribute to improved bone health and a reduced risk of fractures, ultimately enhancing the quality of life for patients.
Interaction of Deninta 60mg Injection with other drugs
Inform the doctor about all the medicines, including prescription medications, over-the-counter medications, nutritional or vitamin supplements, and herbal products. Certain medications may interact with Deninta 60mg Injection and reduce effectiveness by causing undesirable side effects.
More Information about Deninta 60mg Injection
- Deninta 60mg Injection should be stored in the refrigerator at a temperature between 2°C to 8°C (36°F to 46°F).
- Do not freeze it.
- Keep in the original package.
- Keep away from light, moisture, and heat.
- Keep away from children and pets.
- Avoid taking double doses for missed doses.
How to consume Deninta 60mg Injection
Deninta 60mg Injection is given as an injection by healthcare professionals. The dosage and duration of treatment will be based on the individual's condition and response to the medication and should be determined by a healthcare provider.
Safety Advices for Deninta 60mg Injection
The safety of using Deninta 60mg Injection during pregnancy has not been established. Limited studies are available regarding the use of this medication in pregnant women, so it is recommended to use caution and consult a doctor before considering its use during pregnancy.
Whether Deninta 60mg Injection is excreted in milk is unknown. So it is better to consult a healthcare provider if you are a breastfeeding mother before taking this medication.
If you have a lung or respiratory disorders history, it is important to consult your healthcare provider before taking Deninta 60mg Injection.
Deninta 60mg Injection is primarily metabolized in the liver, and its safety has not been extensively studied in individuals with severe liver impairment. It is crucial to communicate any pre-existing liver conditions or changes in liver function to your healthcare provider to ensure this medication's safe and effective use.
It is generally recommended to avoid or limit alcohol consumption while taking Deninta 60mg Injection. Alcohol can interact with this medication, potentially increasing the risk of side effects.
Patients receiving Deninta 60mg Injection should be advised to avoid driving or operating machinery if they experience side effects such as fatigue, dizziness, or blurred vision, impairing a patient's ability to drive or operate machinery safely.
Side Effects of Deninta 60mg Injection
Deninta 60mg Injection can cause side effects like all medications, although not everyone who takes it will experience them.
- Osteonecrosis of the jaw (severe necrosis or death of jaw cells)
- Atypical femoral fractures
- Hypocalcemia (low blood calcium levels)
- Injection site reactions
- Back pain
- Musculoskeletal pain
- Abdominal pain
- Hypophosphatemia (low blood phosphate levels)
Word of Advice
Attend all scheduled appointments and follow-up visits to monitor your response to treatment and address any concerns or side effects. Tell your doctor about your medical history, previous infection, liver disease, and kidney disease. Inform your healthcare provider about any allergies or hypersensitivity reactions you may have. Seek immediate medical attention if you experience severe allergic reactions or other serious side effects. Additionally, Deninta 60mg Injection may affect calcium levels, so monitoring calcium levels and ensuring adequate calcium and vitamin D intake is important. Pregnant and breastfeeding women should consult a doctor before taking this medication. Avoid taking any vaccines during treatment. Regular dental examinations and good oral hygiene practices are recommended to minimize the risk of jaw osteonecrosis.
Q 1. Can Deninta 60mg Injection be used in patients with a history of cancer?
Deninta 60mg Injection is not recommended in patients with a history of certain cancers, such as multiple myeloma or bone metastases. It is important to discuss your medical history and any previous or current cancer diagnoses with your healthcare provider before starting this medication.
Q 2. Can Deninta 60mg Injection be used in patients with kidney problems?
Deninta 60mg Injection is primarily eliminated through the kidneys, so caution is advised in patients with severe renal impairment or end-stage renal disease. Your healthcare provider will assess the potential risks and benefits based on your renal function.
Q 3. Can Deninta 60mg Injection be used as a treatment for osteoporosis in men?
Yes, Deninta 60mg Injection is approved for the treatment of osteoporosis in men at increased risk of fractures. It can help improve bone density and reduce fracture risk in male patients with osteoporosis.
Q 4. Can Deninta 60mg Injection be used in children and adolescents with osteoporosis?
Deninta 60mg Injection is not approved for use in children and adolescents with osteoporosis. The safety and efficacy of this medication have not been established in this population.
Q 5. Can Deninta 60mg Injection be used in individuals with dental implants?
Deninta 60mg Injection use has been associated with a slightly increased risk of jaw osteonecrosis (ONJ). Suppose you have dental implants or are considering getting them. In that case, it is important to discuss this with your dentist and healthcare provider to assess Deninta 60mg Injection's potential risks and benefits.
Q 6. What Are the Side Effects of Deninta 60mg Injection?
Deninta 60mg Injection can cause side effects like injection site reactions, back and musculoskeletal pain, infections, abdominal pain, headache, and low blood phosphate levels. Rare but serious side effects may include osteonecrosis of the jaw, atypical femoral fractures, hypocalcemia, and severe skin reactions.
Fact Box of Deninta 60mg Injection
Molecule name: Denosumab
Therapeutic class: Anti-resorptive agent
|Pharmacological class: Monoclonal Antibodies
2. Bone loss due to hormonal therapy in breast or prostate cancer
3. Multiple myeloma
4. Bone metastases
- Amgen Ltd, Electronic medicines compendium (EMC), [ Revised on 13th May 2023], [ Accessed on 31st May 2023],https://www.medicines.org.uk/emc/files/pil.568.pdf
- Amgen Manufacturing Limited, US Food and Drug Administration, [ Revised on November 2010] [ Accessed on 31st May 2023], https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/125320s007lbl.pdf
- Amgen Manufacturing Limited, US Food and Drug Administration, [ Revised on November 2022] [ Accessed on 31st May 2023], https://www.fda.gov/media/163378/download
MrMed’s primary intention is to ensure that its consumers get information that is reviewed by experts, accurate and trustworthy. The information and contents of this website are for informational purposes only. They are not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please seek the advice of your doctor and discuss all your queries related to any disease or medicine. Do not disregard professional medical advice or delay in seeking it because of something you have read on MrMed. Our mission is to support, not replace, the doctor-patient relationship.
We maintain strict quality controls on all our partner retailers, so that you always get standard quality products.
100% secure and trusted payment protection
We have a new and dynamic return window policy for medicines and healthcare items. Refer FAQs section for more details.